Evidence map›Paper›PMID 28706106›Full record

ArticleBMJ open2017

Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol.

Kwok M Ho, Sudhakar Rao, Stephen Honeybul, Rene Zellweger, Bradley Wibrow, Jeffrey Lipman, Anthony Holley, Alan Kop, Elizabeth Geelhoed, Tomas Corcoran

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Vena caval filters for the prevention of pulmonary embolism.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kwok M HoDepartment of Intensive Care Medicine, Royal Perth Hospital, Perth, Western Australia, Australia.
Sudhakar RaoState Trauma Unit, Royal Perth Hospital, Perth, Western Australia, Australia.
Stephen HoneybulDepartment of Neurosurgery, Royal Perth Hospital and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Rene ZellwegerState Trauma Unit, Royal Perth Hospital, Perth, Western Australia, Australia.
Bradley WibrowDepartment of Intensive Care Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Jeffrey LipmanCritical Care Services, Royal Brisbane and Women's Hospital and University of Queensland, Herston, Queensland, Australia.
Anthony HolleyCritical Care Services, Royal Brisbane and Women's Hospital and University of Queensland, Herston, Queensland, Australia.
Alan KopCentre for Implant Technology and Retrieval Analysis, Department of Medical Engineering and Physics, Royal Perth Hospital, Perth, Western Australia, Australia.
Elizabeth GeelhoedSchool of Population Health, University of Western Australia, Perth, Western Australia, Australia.
Tomas CorcoranSchool of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.
Royal Perth Hospital · AURoyal Brisbane and Women's Hospital · AUUniversity of Western Australia · AUMurdoch University · AUSir Charles Gairdner Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRetrievable inferior vena cava (IVC) filters have been increasingly used in patients with major trauma who have contraindications to anticoagulant prophylaxis as a primary prophylactic measure against venous thromboembolism (VTE). The benefits, risks and cost-effectiveness of such strategy are uncertain. METHODS AND ANALYSIS: Patients with major trauma, defined by an estimated Injury Severity Score >15, who have contraindications to anticoagulant VTE prophylaxis within 72 hours of hospitalisation to the study centre will be eligible for this randomised multicentre controlled trial. After obtaining consent from patients, or the persons responsible for the patients, study patients are randomly allocated to either control or IVC filter, within 72 hours of trauma admission, in a 1:1 ratio by permuted blocks stratified by study centre. The primary outcomes are (1) the composite endpoint of (A) pulmonary embolism (PE) as demonstrated by CT pulmonary angiography, high probability ventilation/perfusion scan, transoesophageal echocardiography (by showing clots within pulmonary arterial trunk), pulmonary angiography or postmortem examination during the same hospitalisation or 90-day after trauma whichever is earlier and (B) hospital mortality; and (2) the total cost of treatment including the costs of an IVC filter, total number of CT and ultrasound scans required, length of intensive care unit and hospital stay, procedures and drugs required to treat PE or complications related to the IVC filters. The study started in June 2015 and the final enrolment target is 240 patients. No interim analysis is planned; incidence of fatal PE is used as safety stopping rule for the trial. ETHICS AND DISSEMINATION: Ethics approval was obtained in all four participating centres in Australia. Results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ACTRN12614000963628; Pre-results.

Indexed as

Vena Cava FiltersHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicResearch DesignRisk AssessmentVenous ThromboembolismWounds and Injuriesadult intensive and critical carethromboembolismtrauma management

Identifiers

PMID28706106
PMCPMC5541499
OpenAlexW2736163003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.